Docket No. ORT-1517

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

vicants : Kordik et al.

Serial No. : 10/001725)

Art Unit:

Filed

: December 22, 2001

Examiner:

For

: AMIDOALKYL-PIPERIDINE and DERIVATIVES USEFUL/FOR THE

and AMIDOALKYL-PIPERA NE

SYSTEM DISORDERS /

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

January 8, 2002 (Date of Deposit)

MARY A. APPOLLINA (Name of applicant, assignee, or Registered Representative)

-

January 8, 2002
(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

RECEIVE

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with $\S1.97(b)$, since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with \(\square\$ the first or ☐second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or

	Please charge Deposit Account No. 10-0750/ // the fee of \$180.00 as set forth in §1.17(p).					
Disclosure State either a Final A under §1.311 but Applicant(s) her Information Disc Accordance with	cordance with §1.97(d), this Information ement is being filed after the mailing date of action under §1.113 or a Notice of Allowance t before the payment of the Issue Fee. The petition(s) for consideration of this closure Statement. Included are: Statement in §1.97(e) as set forth below and the fee of forth in §1.17(p).					
Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.						
-	s of references listed on the attached Form PTO-ed herewith EXCEPT THAT:					
t	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.					
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.					
There are no listed references which are not in the English language.						
The relevance of those listed references which are not in the English language is as follows: a US equivalent for 'EP 496 378 (US 5,597,825 is provided.						

4 6<u>.</u> c

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1517/MAA. This form is submitted in triplicate.
Respectfully submitted, Mary A. Apportina Reg. No. 34087 Attorney for Applicants
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3742 DATED: January 8, 2002



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. PATENT DOCUMENTS

Substitute for form 1449A/PTC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

Application Number	
Filing Date	10/22/ i 0m
First Named Inventor	Kordik et al.
Group Art Unit	0 5 1
Examiner Name	E A
Attorney Docket Number	ORT-517 N

				U.U. TATENT DOCUMENTO		
Examiner Initials	Cite No.1		ind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Riges, Common times, Notice relevant passages and levant figures applear
		5,597,825		Himmelsbach et al.	1/28/1997	
		5,736,559		Himmelsbach et al.	4/7/1998	
		5,922,763		Himmelsbach et al.	7/13/1999	
		4,753,936		Franckowiak et al.	6/28/1988	
		5,892,039		Shue et al.	4/6/1999	
			Î			
						-

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.1	Foreign Patent Document Office ³ Number ⁴ KindCode ⁵			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		EP	0496378A1		Dr. Karl Thomae GmbH	1/22/1992		
		ΕP	0350145A2		Yamanouchi Pharmaceutical Co, Ltd	1/10/1990		
		EP	00/35915		Fuijsawa Phamaceutical Co.	6/22/2000		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.